Aaron & Partners advise Fullbrook Thorpe on multi million pound investment
30th November, 2015
Aaron & Partners has acted for private investment fund Fullbrook Thorpe Investments LLP, which is backed by Andy Leaver (former majority owner of Clinigen Group), in its multi million pound investment in Bionical Limited.
Bionical provides bespoke services for its clients with the aim of becoming the outsource partner of choice for its global pharmaceutical client base.
Fullbrook Thorpe’s investment has provided funding for two recent Bionical acquisitions – Nottingham-based North 51 Group last month and US engagement specialists McCallan Health in August – as well as for further growth capital. This funding facility has been listed on the Channel Islands stock exchange.
Andrew Borkowski, Managing Director of Fullbrook Thorpe Investments, said:
“Bionical is a well-established and respected company in both the UK and the US. It is growing rapidly and providing an increasingly diverse range of truly high quality services to its clients. We are delighted to be playing a significant role in supporting Bionical in this exciting phase of growth.”
Hugh Strickland, Partner in the Corporate Finance team at Aaron & Partners, who advised Fullbrook Thorpe, said:
“It has been really exciting to be involved in such a high profile investment, which has enabled Bionical to increase its services portfolio and will open up further opportunities for the company in the future.”
Ed Bartlett and James Thomas of KPMG Legal in Manchester advised Bionical, with support from Ogiers in the Channel Islands.
For more information please contact the marketing department on 01244 405555 or email [email protected]